↓ Skip to Main Content
Thasso

Thasso

the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in | Register

Main Navigation

  • englishenglish
    • englishenglish
    • françaisfrançais
    • deutschdeutsch
    • italianoitaliano
    • españolespañol
    • portuguêsportuguês
  • thasso
  • thasso: post
  • thasso: interactions
    • thasso: community
    • thasso: video chat
    • thasso: simple chat
    • thasso: patient groups
    • thasso: forum
    • thasso: online meetings (ZOOM)
  • thasso: resources
    • theragenomics: useful links
    • theragenomics: survey at thasso
      • survey participants
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: targeted therapies
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • theragenomics: videos
    • drugs: interactions
    • drugs: general information
    • drugs: adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
  • thasso: academy
    • health authorities
      • European Medicines Agency (EMA)
      • American Food & Drug Administration (FDA)
      • Swissmedic
      • FDA Ghana
      • NAFDAC Nigeria
      • CDSCO India
      • The Medicines Control Council (MCC), South Africa
      • China Food & Drug Administration (CFDA)
      • Health Canada
    • public domain
      • Clinical Pharmacogenetics Implementation Consortium
      • ACMG Genetic Test Fact Sheets
      • Public Health Genomics Knowledge Base
      • The Human Diagnosis Project
      • Phenotypes And Genotypes Database
      • Genetic Alliance UK
      • Genetics Generation
      • Front Line Genomics
      • Alliance for Cancer Gene Therapy (ACGT)
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
      • European Patient Forum
      • Uppsala Monitoring Center
      • World Health Organisation (WHO)
      • von Hippel Lindau Syndrome (VHL)
      • Cerebral Palsy Symptoms
      • Mesothelioma Fund
      • Multiple Myeloma Research Foundation
      • Open Source Pharma (OSP, Medicine for All)
    • theragenomics worldwide
      • The Human Heredity and Health in Africa (H3Africa)
      • The Asia Cohort Consortium
      • GenomeAsia 100K
    • patient & consumer health
      • ThinkGenetic
      • Consumer Health Labs
      • Exercise & Heart Disease
      • UCSF: Eating right for your heart
      • Hormones Matter
      • Living with Arthritis
      • Living with Cannabis
      • Yum of China (Foods)
    • digital therapeutics in theragenomic medicine
      • Digital Therapeutics Alliance (DTA)
      • Digital Health Alliance
    • miscellaneous
      • Partners Health Care / Personalized Medicine
      • Worst Pills / Best Pills
      • Pharmagenomics Research Network
      • Mayo Clinic: Personalized Medicine
      • Patient Power
      • Patient Opinion (UK)
      • Drug Injury Watch (Tom Lamb)
      • Ways To Fund Cancer Treatments
      • MedScape India
      • Swiss Academy of Medical Sciences
      • IDICAP: An Integrated Drug Intervention for Cancer Panel
      • PanDrugs
      • Soccer Genomics
    • companies
      • Moderna
      • BionTech
      • FDNA (Face2Gene Home)
      • IONIS Pharmaceuticals
      • Boehringer Ingelheim Home
      • Bristol-Myers Squipp Home
      • Glaxo Home
      • Novartis Home
      • Roche Home
      • AstraZeneca Home
      • Merck Home
      • Gilead Home
      • Takeda Home
      • Janssen Home
      • Novo Nordisk Home
      • Amgen Home
    • products
      • Axicabtagene ciloleucel (Yescarta)
      • Ledipasvir/Sofosbuvir (Harvoni)
      • Sofosbuvir (Sovaldi)
      • Pembrolizumab (Keytruda)
      • Nivolumab (Opdivo)
      • Sekukinumab (Cosentyx)
      • Rivaroxaban (Xarelto)
      • Valsartan/Amlodipin/HCT (Exforge/HCT)
      • Aripiprazole (Abilify)
      • Rosuvastatin (Crestor)
      • Flibanserin (Addyi)
      • Onasemnogene abeparvovec-xioi (Zolgensma)
      • Voretigene neparvovec (Luxturna)
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • disclaimers
    • policies
    • contact
  • donations $
  • Cookie Policy (EU)
Home › Posts tagged Non-Valvular Atrial Fibrillation (AF)

Tag: Non-Valvular Atrial Fibrillation (AF)

Dabigatran (Pradaxa) Drug Safety Communication: Lower Risk for Stroke and Death, but Higher Risk for GI Bleeding Compared to Warfarin

By Joseph Gut - thasso Posted on May 14, 2014 Posted in Adverse Drug Reaction [ADR], Thasso Post Tagged with American Food & Drug Administration (FDA), Anticoagulation, Bleeding (Brain), Bleeding (Major; Gastointestinal), Dabigatran [Pradaxa], Non-Valvular Atrial Fibrillation (AF), Post Marketing Data, Stroke (Clot-Related), Stroke (Ischemic)

May 13, 2014 – The Pradaxa story continues. See the latest MedWatch Drug Safety Communication, posted on 05/13/2014. ISSUE: The FDA recently completed a new study in Medicare patients comparing Pradaxa to warfarin, for risk of ischemic or clot-related stroke,  bleeding …

Dabigatran (Pradaxa) Drug Safety Communication: Lower Risk for Stroke and Death, but Higher Risk for GI Bleeding Compared to Warfarin Read more »

In/Out

  • Log in

Optional: Social Subscribe/Login

thasso: donate

We need your help. Please support the development of thasso through donations. Thank you.    Nous avons besoin de votre aide. S'il vous plaît, vous pouvez soutenir le développement de thasso grâce à des dons. Merci.    Wir brauchen Ihre Hilfe. Bitte unterstützen Sie die Entwicklung von thasso durch Spenden. Vielen Dank.    Abbiamo bisogno del tuo aiuto. Si prega di sostenere lo sviluppo di thasso attraverso donazioni. Grazie.    Nós precisamos da sua ajuda. Por favor, apoie o desenvolvimento de thasso através de doações. Obrigada.     Necesitamos tu ayuda. Por favor apoye el desarrollo de thasso con donaciones. Muchas gracias.

thasso: conditions

thasso: newest tweets

Tweets by thasso_info

 

RSS FDA press releases

  • FDA Roundup: May 26, 2023 May 26, 2023
  • FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults May 25, 2023
  • FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria May 23, 2023
  • FDA Roundup: May 23, 2023 May 23, 2023
  • FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder May 23, 2023

RSS FDA MedWatch

  • FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions. May 26, 2023
  • 2023 Medical Device Recalls May 25, 2023
  • SD BioSensor, Inc. Recalls Certain Pilot COVID-19 At-Home Tests for Potential Bacteria Contamination May 25, 2023
  • Draeger Medical Recalls Seattle PAP Plus and Breathing Circuit/Anesthesia Kits for Risk of Loose or Detached Components That Can Restrict Breathing Support May 24, 2023
  • ICU Medical Recalls Replacement Batteries for Plum 360, Plum A+, and Plum A+3 Infusion Systems Due to Diminished Battery Life that May Impact Infusion Delivery May 22, 2023

RSS EMA Press releases

  • EMA business hours over Whit Monday, 29 May, , 26/05/2023 May 26, 2023
  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 May 2023, CHMP, 26/05/2023 May 26, 2023
  • EMA recommends revocation of authorisation for sickle cell disease medicine Adakveo, CHMP, 26/05/2023 May 26, 2023
  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023, CHMP, 26/04/2023 May 26, 2023
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10 - 12 May 2023, PRAC, 12/05/2023 May 22, 2023

RSS random genetics

  • Study reveals underlying genetic risks for type of heart attack largely affecting younger women May 29, 2023
    Research led by the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Center (BRC) and Universite Paris Cite, and supported by worldwide partners in Canada, the U.S. and Australia, has identified new genes that are associated with an increased risk of a type of heart attack primarily affecting young to middle-aged women. […]
  • CRISPR studies identify many promising therapeutic targets for multiple myeloma May 29, 2023
    New research from Dana-Farber Cancer Institute has identified 116 genes as key molecular vulnerabilities for multiple myeloma. Most of these genes are potential leads for the discovery of new therapies for this disease. The study was published in Nature Cancer.
  • Gene therapy rescues hearing for the first time in aged mouse models May 26, 2023
    By 2050, one in 10 individuals are expected to live with some form of hearing loss. Of the hundreds of millions of cases of hearing loss affecting individuals worldwide, genetic hearing loss is often the most difficult to treat.
  • Rethinking the protein inhibitor approach to cancer therapy May 26, 2023
    A new method than enables researchers to dial up or tone down the amount of a certain metastatic protein inhibitor (BACH1) within a cell could provide a new path in cancer research that reassesses the effectiveness of protein inhibitors to treat disease. Led by a team of Stony Brook University scientists, the research involves adjusting […]
  • Mapping the genetic history of French Canadians through space and time May 25, 2023
    Though we all share common ancestors ranging from a few generations to hundreds of thousands of years, genealogies that relate all of us are often forgotten over time. A new McGill University-led study published in Science is now providing insight into the complex relationship between human migration and genetic variation, using a unique genealogical dataset […]

Recent Comments

  • Joseph Gut - thasso on Is there pre-emptive genotyping to avoid adverse drug effects (ADRs)?: “Just testing. https://www.alphamannosidosis.com/en/for-patients-caregivers/disease-information/?utm_source=google&utm_medium=cpc&utm_campaign=AlphamannSearch_Paziente2020&gclid=EAIaIQobChMI2Pv7wNaC_AIVWud3Ch1J8AMPEAAYAiAAEgJGI_D_BwE/” Dec 18, 08:50
  • Joseph Gut - thasso on Including Africa in the research on rare genetic diseases: A must!: “The genetic diversity of African populations with respect to rare genetic diseases will help to better understand the mechanisms behind…” Dec 18, 04:09
  • Joseph Gut - thasso on The sixth sense: Are there genes associated with it?: “Does this now work as intended?” Dec 18, 03:55
  • David Walliams on Is genetic testing of value for ALS patients?: “CURED FROM GENITAL HERPES More than 5 years ago I was in pain with this deadly herpes virus, A few…” Nov 7, 16:08
  • Raul Malkovic on Is genetic testing of value for ALS patients?: “HOW MY WIFE GOT CURED FROM ALS Below is how i got a cure for my wife who suffered from Amyotrophic Lateral Sclerosis…” Nov 6, 21:18

Tag Cloud

Adverse Drug Reaction (ADR) African American Allelic Variant Allelic Variants American Food & Drug Administration (FDA) American Food & Drug Administration (FDA) Boxed Warning Breast Cancer Canagliflozin (Invokana) Cancer Children Committee for Medicinal Products for Human Use (CHMP) Companion Test Covid-19 Disease Diabetes Drug Induced Liver Injury (DILI) Epidermal Growth Factor Receptor (EGFR) Ethnicity European Medicine Agency (EMA) European Medicines Agency (EMA) Food and Drug Administration (FDA) Gene Therapy Genetic Background Genetic Predisposition Genetic Testing Genotype Health Canada Non-Small Cell Lung Cancer (NSCLC) Pembrolizumab [Keytruda] Personalized Medicine Phenotype Progressive Multifocal Leukoencephalopathy (PML) Rare Disease Risk Evaluation and Mitigation Strategy (REMS) SARS-CoV-2 Schizophrenia Sildenafil [Viagra] Stevens Johnson Syndrome [SJS] Targeted Therapy ThassoBase Thasso Post Theragenomic Medicine Toxic Epidermal Necrolysis (TEN) Type 2 Diabetes Vemurafenib [Zelboraf]

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
© 2023 Thasso | Powered by Responsive Theme
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}